PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1485770
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1485770
Plasmid DNA Contract Manufacturing Market size was valued at USD 381.54 Million in 2023, expanding at a CAGR of 19.43% from 2024 to 2032.
The Plasmid DNA Contract Manufacturing Market involves the outsourcing of production processes related to plasmid DNA, which is widely used in biotechnology and pharmaceutical research. The rising demand for gene therapy and vaccine development boosted the growth of contract manufacturing services for plasmid DNA. However, restraints such as regulatory challenges and the complexity of manufacturing processes pose hurdles to market expansion. Opportunities lie in the rising investments in biotechnology and the development of novel therapies, which create a conducive environment for contract manufacturers to capitalize on the growing demand for plasmid DNA.
Plasmid DNA Contract Manufacturing Market- Market Dynamics
The increasing demand for plasmid (pDNA) DNA and increasing research and development activities by key players in the market
The demand for plasmid DNA is witnessing a notable upsurge, driven by increasing research and development activities undertaken by prominent market players. This trend is indicative of the growing importance of plasmid DNA in various biotechnological applications, including gene therapy, vaccine development, and genetic engineering. Furthermore, contract manufacturing organizations are contributing to the expansion of the plasmid DNA market. These efforts are aimed at addressing unmet medical needs and driving innovation in the biotechnology sector.
Plasmid DNA Contract Manufacturing Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 19.43% over the forecast period (2024-2032)
Based on Plasmid Size and Complexity segmentation, Large Plasmids were predicted to show maximum market share in the year 2023
Based on Service Type segmentation, Plasmid DNA Manufacturing was the leading type in 2023
Based on Therapeutic Area segmentation, Oncology was the leading type in 2023
On the basis of region, North America was the leading revenue generator in 2023
The Global Plasmid DNA Contract Manufacturing Market is segmented on the basis of Plasmid Size and Complexity, Service Type, Therapeutic Area, Application, and Region.
The market is divided into three categories based on Plasmid Size and Complexity: Plasmids come in different sizes and complexities, catering to various genetic engineering needs. Small plasmids are compact DNA molecules ideal for basic genetic engineering tasks, while large plasmids offer greater gene-carrying capacity, suiting advanced biotechnology applications.
The market is divided into four categories based on Service Type: Plasmid DNA contract manufacturing offers diverse services, including production, optimization, testing, and formulation. Analytical testing ensures product quality, while formulation and fill-finish services prepare products for distribution.
Plasmid DNA Contract Manufacturing Market- Geographical Insights
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.
North America leads in market share due to a strong presence of biotechnology and pharmaceutical companies, coupled with favorable regulatory frameworks. Europe follows closely, with robust investments in research and development and a well-established biomanufacturing infrastructure. The Asia-Pacific region shows significant growth potential, driven by increasing investments in biotechnology and contract manufacturing services.
Several key players include established biopharmaceutical contract manufacturing organizations (CMOs) such as Aldevron, Catalent, and Thermo Fisher Scientific. These companies offer comprehensive services ranging from plasmid DNA production to purification and analytical testing. Additionally, emerging CMOs and biotechnology startups contribute to market diversity, offering specialized expertise and niche services. Collaboration between contract manufacturers and biotechnology firms further intensifies competition, as companies strive to offer innovative solutions and expand their global footprint.
In March 2024, Novel Bio entered into a product development and scale-up agreement with Culture Biosciences to produce plasmid DNA. According to the agreement, Novel Bio will assist Culture Biosciences in expediting the development of scalable fermentation processes for their proprietary NBx Platform(TM), aimed at enhancing plasmid DNA production.
In June 2023, INADcure Foundation unveiled a manufacturing partnership with Charles River Laboratories. In this collaboration, Charles River Laboratories will oversee the production of high-quality plasmid DNA (pDNA) for phase I/II clinical trials focused on a gene therapy targeting Infantile Neuroaxonal Dystrophy.
GLOBAL PLASMID DNA CONTRACT MANUFACTURING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Aldevron, LLC
Catalent, Inc.
Cell and Gene Therapy Catapult (CGT Catapult)
Cobra Biologics (a subsidiary of Cognate BioServices)
Codex DNA, Inc.
Eurofins Scientific
Fujifilm Diosynth Biotechnologies
Kaneka Corporation
Lonza Group Ltd.
MilliporeSigma (a business of Merck KGaA)
PlasmidFactory GmbH & Co. KG
Sirion Biotech GmbH
Thermo Fisher Scientific Inc.
VGXI, Inc. (a subsidiary of GeneOne Life Science Inc.)
Wuxi Biologics
Others